

Visala G. Goswitz, Ph.D.

Patent Agent

Overview

Visala C. Goswitz has over 15 years of experience in the preparation and prosecution of patent applications in areas of Biotechnology, Chemistry and Medical Devices, including Immunology, Molecular Biology, Microbiology and Food Science. She also has extensive experience in preparing and prosecuting patent applications related to therapies using T-cells. Visala is also experienced in patent prosecution internationally.

Visala is also experienced in conducting research in the areas of genetics and cell biology. Her research has included structure and function studies on membrane transport proteins and oxidases. Visala has also conducted research related to eukaryotic and prokaryotic respiratory chain and opiate receptors and is experienced in all aspects of microbiological techniques and cell biology. Visala has also worked as an Assistant Professor at the University of St. Thomas.



Contact Information

E-mail: vgoswitz@wck.com
Phone: 1-612-334-3222
Direct: 1-612-852-0617
Fax: 1-612-334-3312

900 Second Avenue South
Suite 1400
Minneapolis, MN 55402

Admissions

United States Patent and
Trademark Office

Education

University of Illinois at Urbana-
Champaign, Ph. D. Biochemistry,
1990

Carleton College, B.A. Chemistry,
1984

Areas of Technical Expertis

- Biotechnology
- Molecular Biology
- Microbiology
- Microbiological Techniques
- Food Science
- Chemistry
- Medical Devices
- Immunology
- Genetics
- Cell Biology

Exemplary Patents

- U.S. 8,679,841; Allogeneic cell compositions with cross-linked CD3/CD28
- U.S. 8,641,872; Non-thermal plasma synthesis with carbon component
- U.S. 8,354,276; T-cell compositions that elicit type I cytokine response
- U.S. 8,313,944; Methods to cause differentiation of T-cells for use in cell therapy
- U.S. 8,298,587; Method for stimulating a therapeutic immune effect in a patient
- U.S. 8,273,377; Method for allogeneic cell therapy
- U.S. 8,137,679; Immunogen adherence inhibitor directed to *Lactobacillus* organisms and method of making and using it
- U.S. 8,076,135; Method of preparing a treatment effective amount of allogeneic T-cells
- U.S. 6,228,634; Thermal cycling or temperature control device and method using alumina plate
- U.S. 6,218,500; Urethane resins
- U.S. 6,193,705; Flow assisted catheter

Publications

Sawicki, Z.P., **V.C. Goswitz** and A.M. Prose. Patenting Biologicals Myriad Issues and Options in the wake of *Myriad*. *Bench and Bar of Minnesota* Sept. 2013. page 22-26.

Goswitz, V.C., Sawicki, Z.P. Cancer Therapy Based on a Mechanism of Action for Controlling the Immune System and the Resulting Patent Portfolio. *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery*. (January 2013) Vol. 7, 1-10.

Goswitz, V.C., E.A. Matzke, M.R. Taylor, A.E. Jessen-Marshall and R.J. Brooker. Structural topology of transmembrane helix 10 in the lactose permease of *E. coli*. *J. Biol Chem.* (1996) 271, 21927-21932.

Goswitz, V.C. and R.J. Brooker. Structural features of the uniporter/ symporter/ antiporter superfamily. *Protein Sci.* (1995) 4, 534-537.

Calhoun, M.W., L.J. Lemieux, J.W. Thomas, J.J. Hill, **V.C. Goswitz** and R. B. Gennis. Spectroscopic characterization of mutants supports the assignment of histidine-419 as the axial ligand of heme o in the binuclear center of the cytochrome bo ubiquinol oxidase in *E. coli*. *Biochemistry* (1993) 32, 13254-13261.

Goswitz, V.C. and R. J. Brooker. Isolation of lactose permease mutants which recognize arabinose. *Membrane Bioch.* (1993) 10. 61-70.

Hill J.J., **V.C. Goswitz**, M. Calhoun, J.A. Garcia-Horsman, L. Lemieux, J.O. Alben and R.B. Gennis. Demonstration by FTIR that the bo-type ubiquinol oxidase of *E.coli* contains a heme-copper binuclear center similar to that in cytochrome c oxidase and that proper assembly of the binuclear center requires the *cyoE* gene product. *Biochemistry*. (1992) 31, 11435-11440.

Minghetti, K.C., **V.C. Goswitz**, N.E. Gabriel, S. Chan and R.B. Gennis. Modified, large scale purification of the cytochrome o complex (bo-type oxidase) of *E coli* yields a two heme/one copper terminal oxidase with high specific activity. *Biochemistry* (1992) 31, 6917-6924.

Cotter, P.A., **V. Chepuri**, R.B. Gennis and R.P. Gunsalus. Cytochrome o (*cyoABCDE*) and d (*cydAB*) oxidase gene expression in *E. coli* is regulated by oxygen, pH and the *fnr* gene product. *J.Bact.* (1990) 172, 6333-6338.

Iuchi, S., **V. Chepuri**, H.A. Fu, R. B. Gennis and E.C.C. Lin. The requirement of terminal cytochromes in the generation of aerobic signal for the *arc* regulatory system in *E. coli*: a study utilizing deletions and *lac* fusions of *cyo* and *cyd*. *J. Bact.* (1990) 172, 6020-6025.

Chepuri, V., L. Lemieux, J. Hill, J.O. Alben and R.B. Gennis. Recent studies on the cytochrome o oxidase complex in *E.coli*. *Biochim. Biophys. Acta.* (1990) 1018, 124-127.

Chepuri, V. and R.B. Gennis. The use of gene fusions to determine the topology of all of the subunits of the cytochrome o oxidase complex in *E. coli* *J. Biol. Chem.* (1990) 265, 12978-12986.

Chepuri, V., L. Lemieux, D.C.T. Au and R.B. Gennis. The sequence of the *cyo* operon indicates substantial structural similarities between the cytochrome o ubiquinol oxidase of *E. coli* and the aa₃-type family of cytochrome c oxidases. *J. Biol. Chem.* (1990) 265, 11185-11192.

Saraste, M., M. Raitio, T. Jalli, **V. Chepuri**, L. Lemieux, and R.B. Gennis. Cytochrome o from *E.coli* is structurally related to cytochrome aa₃. *Ann. Of the New York Acad. Of Sci.* (1988) 550 314-324.